AZN•benzinga•
The European Union Has Recommended Approving AstraZeneca's Imfinzi (Durvalumab) For Adult Patients With Resectable Muscle-invasive Bladder Cancer In Combination With Gemcitabine And Cisplatin As Neoadjuvant Treatment, Followed By Imfinzi As Monotherapy Ad
Summary
No summary available.
Original Article
Read the full article from the original source for complete details and context.
Read Full ArticleArticle published on May 27, 2025 by benzinga